Targeted missile drug hunts down hidden leukemia cells
NCT ID NCT03737955
Summary
This trial is testing whether a targeted drug called gemtuzumab ozogamicin can eliminate hidden cancer cells in adults with acute myeloid leukemia (AML) who are in remission but still have measurable residual disease. The drug works like a guided missile—it attaches to specific markers on cancer cells and delivers a chemotherapy payload directly to them. Researchers want to see if this approach can clear these remaining cells and potentially prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutchinson Cancer Center/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.